Literature DB >> 24742232

Routine diagnostic ureteroscopy for suspected upper tract transitional-cell carcinoma.

Alexander Tsivian1, Matvey Tsivian, Yury Stanevsky, Eli Tavdy, A Ami Sidi.   

Abstract

BACKGROUND AND
PURPOSE: Upper tract transitional-cell carcinoma (utTCC) is uncommon. Standard evaluation includes imaging, cytology, and cystoscopy and gold standard treatment is nephroureterectomy (NU) with solid oncologic outcomes and elevated morbidity. In this study, we report on the value of including routine ureteroscopy (URS) for evaluating suspected utTCC in shifting the treatment toward less morbid options and increasing preoperative diagnostic accuracy. PATIENTS AND METHODS: Records of patients presenting between 2002 and 2013 with suspected utTCC were reviewed. Since 2010, URS has been included routinely in the evaluation protocol. Demographic, clinical, and pathologic characteristics were recorded and compared between earlier experience (group 1) and with routine URS (group 2). In addition, the number needed to treat (NNT) was calculated with respect to shifting the procedure choice from NU to other options as well as in reducing the rates of misdiagnoses.
RESULTS: A total of 118 patients were included: 63 in group 1 and 55 in group 2. The pathology-confirmed TCC rates were comparable between the two groups (78 vs 85%). The rates of NU decreased with routine URS use from 89% to 69% (P=0.011, NNT=5.05) whereby patients were treated endoscopically or with distal ureterectomy. Misdiagnoses decreased from 15.5% to 2.1% with routine URS (P=0.021, NNT=7.44). Sepsis occurred in two patients after URS.
CONCLUSIONS: In this initial study, routine URS evaluation for suspected utTCC appears to enable an increased use of other treatment choices rather then NU, with an estimated five URS avoiding one NU. Moreover, routine URS reduced the rates of misdiagnosis of TCC. Complications associated with URS may add an additional morbidity burden, however.

Entities:  

Mesh:

Year:  2014        PMID: 24742232     DOI: 10.1089/end.2013.0703

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  5 in total

Review 1.  [Ureterorenoscopy].

Authors:  A J Gross; J Rassweiler; K D Sievert; A Miernik; J Westphal; H Leyh; T R W Herrmann; P Olbert; A Häcker; A Bachmann; R Homberg; J Klein; M Schoenthaler; C Netsch
Journal:  Urologe A       Date:  2017-03       Impact factor: 0.639

Review 2.  Pictorial review of tips and tricks for ureteroscopy and stone treatment: an essential guide for urologists from PETRA research consortium.

Authors:  Bhaskar K Somani; Achilles Ploumidis; Athanasios Pappas; Steeve Doizi; Omikunle Babawale; Laurian Dragos; Emre Sener; Michele Talso; Tzevat Tefik; Peter Kronenberg; Esteban Emiliani; Luca Villa; Guido Kamphuis; Silvia Proietti; Olivier Traxer
Journal:  Transl Androl Urol       Date:  2019-09

Review 3.  Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC).

Authors:  Francesco Soria; Shahrokh F Shariat; Seth P Lerner; Hans-Martin Fritsche; Michael Rink; Wassim Kassouf; Philippe E Spiess; Yair Lotan; Dingwei Ye; Mario I Fernández; Eiji Kikuchi; Daher C Chade; Marko Babjuk; Arthur P Grollman; George N Thalmann
Journal:  World J Urol       Date:  2016-09-07       Impact factor: 4.226

Review 4.  Diagnostic ureteroscopy for upper tract urothelial carcinoma: friend or foe?

Authors:  Angelo Territo; Andrea Gallioli; Iacopo Meneghetti; Matteo Fontana; Jordi Huguet; Joan Palou; Alberto Breda
Journal:  Arab J Urol       Date:  2021-02-16

5.  Diagnostic outcome of ureteroscopy in urothelial carcinoma of the upper urinary tract: Incidence of later cancer detection and its risk factors after the first examination.

Authors:  Norihiro Murahashi; Takashige Abe; Nobuo Shinohara; Sachiyo Murai; Toru Harabayashi; Ataru Sazawa; Satoru Maruyama; Kunihiko Tsuchiya; Naoto Miyajima; Kanako Hatanaka; Katsuya Nonomura
Journal:  BMC Urol       Date:  2015-09-04       Impact factor: 2.264

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.